• If you are wondering whether BridgeBio Pharma's share price still makes sense after a strong run, this article focuses on what the numbers say about value rather than the excitement around the stock.
• The stock trades at US$77.81, with returns of 2.0% over the past week, 2.7% over the past month, a slight year to date decline of 0.5%, a 112.2% return over the past year, a very large 3 year gain that is around 7x, and a 35.5% return over 5 years.
• Recent news around BridgeBio has centered on its pipeline progress, regulatory updates and partnership activity. Together, these factors help explain why investors have paid close attention to the stock price and provide useful context for understanding how sentiment and perceived risk have shifted over time.
• On Simply Wall St's valuation checks, BridgeBio scores 2 out of 6, which suggests some areas may screen as potentially cheap while others do not. We will look at how different valuation approaches arrive at that view, then finish with a more complete way to think about what the stock could be worth.

BridgeBio Pharma scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: BridgeBio Pharma Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes projected future cash flows and then discounts them back into today’s dollars to estimate what the business might be worth right now.

For BridgeBio Pharma, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in US$. The latest twelve month free cash flow is a loss of $597.3 million. Analysts have provided free cash flow estimates up to 2030, with Simply Wall St extrapolating beyond that. Within the next decade, projected free cash flow reaches $1,917.3 million in 2030, with intermediate years stepping from a $172.9 million loss in 2026 to $317.2 million in 2027 and $889.0 million in 2028.

After discounting these projected cash flows back to today, the model arrives at an estimated intrinsic value of about $273.91 per share. Compared with the current share price of $77.81, this DCF output suggests the stock screens as materially undervalued, with an implied discount of 71.6%.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests BridgeBio Pharma is undervalued by 71.6%. Track this in your watchlist or portfolio, or discover 885 more undervalued stocks based on cash flows.

Approach 2: BridgeBio Pharma Price vs Sales

For companies that are not yet profitable, P/S is often the cleaner yardstick because it focuses on what the market is paying for each dollar of revenue, rather than earnings that can swing with research and development or one off items.

In general, higher growth expectations and lower perceived risk can justify a higher “normal” P/S multiple. Slower growth or higher uncertainty tends to pull that normal range down. So the question is what looks reasonable for BridgeBio today.

BridgeBio currently trades on a P/S of 42.38x. That is well above the Biotechs industry average of 11.69x and also above the peer group average of 18.58x. Simply Wall St’s Fair Ratio for BridgeBio is 26.60x, which is their proprietary view of what the P/S might be given the company’s earnings growth profile, industry, profit margins, market cap and risk factors.

The Fair Ratio helps you look past simple peer and industry comparisons because it adjusts for company specific drivers rather than assuming one size fits all. Comparing 42.38x to the Fair Ratio of 26.60x suggests the shares screen as expensive on this metric.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1424 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your BridgeBio Pharma Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which give you a simple story behind the numbers such as your fair value, and your expectations for future revenue, earnings and margins.

A Narrative is your view of what BridgeBio is trying to achieve, how that might show up in its financials over time, and what you think a fair value per share could be based on that path. It links the company’s story to a set of forecasts, and then to a fair value that you can compare to today’s price to help decide whether you see BridgeBio as more attractive or less attractive right now.

On Simply Wall St, you can create and explore Narratives on the Community page, where millions of investors use them as an easy tool that automatically updates when new information such as earnings or news is added. For BridgeBio, one investor might build a Narrative with a higher fair value based on optimistic assumptions for the pipeline, while another might set a lower fair value if they prefer more cautious forecasts.

Do you think there's more to the story for BridgeBio Pharma? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.